Prækliniske forsøg tyder på, at topotecans plasmaproteinbinding er lav (35%) og fordelingen mellem blodceller og plasma er omtrent homogen.
Preclinical studies indicate plasma protein binding of topotecan is low (35%) and distribution between blood cells and plasma was fairly homogeneous.